{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:26:42Z","timestamp":1793039202270,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","award":["68384005"],"award-info":[{"award-number":["68384005"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10067-024-06980-x","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T06:01:26Z","timestamp":1714802486000},"page":"2133-2138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-8807","authenticated-orcid":false,"given":"M. A. A.","family":"Opdam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.den","family":"Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J. F.","family":"van den Bemt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"van de Wiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"van Ballegooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van Crevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"6","key":"6980_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg J-E, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, M\u00fcller-Ladner U, Mysler EF, da Silva JAP, Po\u00f3r G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6980_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52(1):53\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/kes305","journal-title":"Rheumatology (Oxford)"},{"issue":"9990","key":"6980_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/s0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, Ghogomu ET, Coyle D, Clifford T, Tugwell P, Wells GA (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386(9990):258\u2013265. https:\/\/doi.org\/10.1016\/s0140-6736(14)61704-9","journal-title":"Lancet"},{"issue":"10","key":"6980_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 58(10):1755\u20131766. https:\/\/doi.org\/10.1093\/rheumatology\/kez087","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"6980_CR5","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL (2016) Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75(10):1843\u20131847. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209131","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"6980_CR6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.7326\/0003-4819-124-11-199606010-00008","volume":"124","author":"MJ Glesby","year":"1996","unstructured":"Glesby MJ, Hoover DR (1996) Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 124(11):999\u20131005. https:\/\/doi.org\/10.7326\/0003-4819-124-11-199606010-00008","journal-title":"Ann Intern Med"},{"issue":"3","key":"6980_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth CM, Tannock IF (2014) Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 110(3):551\u2013555. https:\/\/doi.org\/10.1038\/bjc.2013.725","journal-title":"Br J Cancer"},{"issue":"2","key":"6980_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/2229-516x.157148","volume":"5","author":"R Mahajan","year":"2015","unstructured":"Mahajan R (2015) Real world data: additional source for making clinical decisions. Int J Appl Basic Med Res 5(2):82. https:\/\/doi.org\/10.4103\/2229-516x.157148","journal-title":"Int J Appl Basic Med Res"},{"issue":"5","key":"6980_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE (2011) High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70(5):785\u2013791. https:\/\/doi.org\/10.1136\/ard.2010.128637","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"6980_CR10","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2016.16435","volume":"316","author":"DN Kyriacou","year":"2016","unstructured":"Kyriacou DN, Lewis RJ (2016) Confounding by indication in clinical research. JAMA 316(17):1818\u20131819. https:\/\/doi.org\/10.1001\/jama.2016.16435","journal-title":"JAMA"},{"issue":"2","key":"6980_CR11","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1097\/rhu.0000000000001749","volume":"28","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Marques FB (2022) The risk of infections associated with jak inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol 28(2):e407\u2013e414. https:\/\/doi.org\/10.1097\/rhu.0000000000001749","journal-title":"J Clin Rheumatol"},{"key":"6980_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, Checchio T, Tensfeldt TG, Hoffman E, Riese R, Boy M, G\u00f3mez-Reino JJ (2015) Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 17:362. https:\/\/doi.org\/10.1186\/s13075-015-0880-2","journal-title":"Arthritis Res Ther"},{"key":"6980_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/jir.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R (2020) JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res 13:519\u2013531. https:\/\/doi.org\/10.2147\/jir.S219586","journal-title":"J Inflamm Res"},{"issue":"11","key":"6980_CR14","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/ard-2022-222405","volume":"81","author":"AR Balanescu","year":"2022","unstructured":"Balanescu AR, Citera G, Pascual-Ramos V, Bhatt DL, Connell CA, Gold D, Chen AS, Sawyerr G, Shapiro AB, Pope JE, Schulze-Koops H (2022) Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis 81(11):1491\u20131503. https:\/\/doi.org\/10.1136\/ard-2022-222405","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6980_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4103\/ijdvl.IJDVL_1021_16","volume":"84","author":"E Koshy","year":"2018","unstructured":"Koshy E, Mengting L, Kumar H, Jianbo W (2018) Epidemiology, treatment and prevention of herpes zoster: a comprehensive review. Indian J Dermatol Venereol Leprol 84(3):251\u2013262. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_1021_16","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06980-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06980-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06980-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:06:58Z","timestamp":1716394018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06980-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6980"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06980-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,4]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MO, NdB, BvdB, KM, KvdW, HvB, and RvC report no conflicts of interest. AdB: Grants for quality-of-care projects and research on RA, PsA and axSpA from Abbvie, Galapagos, Pfizer, Novartis, Lilly, Sanofi, and Gilead to the Institution\/Department of Rheumatology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}